The pharma sector in India is reeling after the National Pharmaceutical Pricing Authority said it's capping prices on about 100 drugs to treat diabetes and heart disease. And the company that could suffer most isn't India-based.
While geopolitical instability in Eastern Europe would appear to make Russia a risky bet, the size of the market and incoming targets on drug production mean the likes of Abbott Laboratories are still investing. For companies unwilling or unable to strike deals like Abbott's $495 million buyout of Veropharm, a new option is tipped to emerge: CMOs.
In the weeks since Narendra Modi won the Indian election, drugmakers and other manufacturers have looked expectantly to the new government's first budget. Now, with the budget nearing, manufacturers have opened up about what they want and politicians from the United Kingdom have flown in to unveil Cipla's £100 million ($172 million) investment in the former colonial power.
Pfizer has a manufacturing plant underway in Saudi Arabia that is slated to be operating next year. But the drugmaker has just struck a deal that will give it access to additional capacity, as well as products, in that country.
Parexel International is looking to broaden its presence in the Middle East and North Africa, snapping up Turkish CRO Atlas Medical Services.
Intuitive Surgical is kicking off direct sales of its da Vinci Surgical Systems in Japan, continuing its push in emerging markets and hoping to generate positive numbers after a year of sluggish sales.
India-based Cipla has been expanding its manufacturing footprint outside of its base in India and has now made the jump across the Arabian Sea to Yemen.
Novotech, which bills itself as Australia's largest CRO, has signed a deal with a South Korean outfit to help bolster the country's status among global drug development locales.
A team from the Massachusetts Institute of Technology is a finalist for the 2014 Hult Prize after developing a simple wound-therapy device to improve the lives of those lacking access to adequate medical care.
Roche and Cipla are writing a new chapter in the bitter battles that have been fought by Western drugmakers over their patents in India. They are in mediation over the patent for Roche's blockbuster cancer fighter Tarceva, in what may be the first case to take this route.